Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback